Search the website

Fulltext search

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Withdrawn applications Remove Withdrawn applications filter Referrals Remove Referrals filter

Product number

Authorisation status

Authorised (2) Apply Authorised filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (1) Apply Initial authorisation filter

Withdrawal date

From:

To:

Referral name

Referral status

European Commission final decision (1) Apply European Commission final decision filter

Referral type

Article 20 procedures (1) Apply Article 20 procedures filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (1) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally authorised product(s) (1) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (1) Apply Risk minimisation measures filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter Biosimilar (6) Apply Biosimilar filter Conditional approval (2) Apply Conditional approval filter Exceptional circumstances (1) Apply Exceptional circumstances filter

Related medicine

Therapeutic area

Topic

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

4 results

Remove all filtersRemove all filters

Keyword epoetin Remove keyword

Categories Human Remove Human filter

Medicine Summaries of opinion Remove Summaries of opinion filter Referrals Remove Referrals filter Withdrawn applications Remove Withdrawn applications filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter

Medicine type Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter Accelerated assessment Remove Accelerated assessment filter

Sort by

List item

Human medicine European public assessment report (EPAR): Rubraca (updated)

rucaparib camsylate, Ovarian Neoplasms
Date of authorisation: 23/05/2018, , , Revision: 5, Authorised, Last updated: 14/01/2021
List item

Human medicine European public assessment report (EPAR): Elaprase

idursulfase, Mucopolysaccharidosis II
Date of authorisation: 08/01/2007, , , Revision: 20, Authorised, Last updated: 24/06/2020
List item

Withdrawn application: Orathecin

date of withdrawal: 19/01/2006, Initial authorisation, Last updated: 23/01/2006
List item

Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)

daclatasvir / dasabuvir / sofosbuvir / ledipasvir / simeprevir / ombitasvir/paritaprevir / ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017

4 results

Human medicine European public assessment report (EPAR): Rubraca (updated)

Human medicine European public assessment report (EPAR): Elaprase

Withdrawn application: Orathecin

Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)